All sunlamps should be reclassified as Class III devices because of their known risks, especially the increased likelihood of developing the most serious type of skin cancer.
Patients with kidney cancer have many options for drug therapy but often experience bad side effects. As the FDA considers another drug option, we don’t think the science is good enough to suggest patients will have a longer and better quality life on this new drug. Instead, we recommend waiting for more clinical data to give doctors and patients a clear idea of when tivozanib would be beneficial rather than cause more harm.
Dr. Yttri testifies at an FDA public hearing that a new, expedited pathway for drug approval is poorly-defined and would promote unproven drugs to high-risk patients.
Dr. Zuckerman states that loopholes in the FDA law, including compounding pharmacies, have allowed hundreds of people to get sick with meningitis and several to die. The VALID Compounding Act is designed to close the loopholes that are so harmful to patients.
Brandel France de Bravo, MPH, testifies on the safety and efficacy of a new device to examine the margins of tissue removed during a lumpectomy to make sure all the breast cancer was removed.
Sonia Nagda, the senior fellow of the Cancer Prevention and Treatment Fund testifies at an FDA advisory meeting on a drug that prevents blood clots in patients taking chemotherapy.